Back in the summer of 2017, an unknown Chinese biotech called Legend jumped into ASCO and disrupted the rep bluebird had carefully erected for itself as the breakaway leader among companies developing a BCMA-targeting CAR-T for multiple myeloma, offering up regular looks at one of the industry’s top development programs.
Legend offered startling proof-of-concept data to suggest that they could leapfrog the pack and land among the top companies pioneering the field. Soon after J&J followed up with a rich $350 million cash upfront to partner with Legend, offering their endorsement that the biotech was no fly-by-night pretender to the throne.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,000+ biopharma pros who read Endpoints News by email every day.Free Subscription